The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

We are providing an update to our previously published review paper on inhaled
nanoparticles, thus updating with the most recent reports in the literature. The field of …

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3
PH in the most recent classification system. Prevalence of these diseases is increasing over …

Extensive research into prodrug modification of active pharmaceutical ingredients and
nanoparticle drug delivery systems has led to unprecedented levels of control over the …

Nanoparticles are exclusively suitable for studying and developing potential therapies
against cardiovascular diseases (CVD) because of their size, fine-tunable properties, and …

Excess macrophages and smooth muscle cells (SMCs) characterize many cardiovascular
diseases, but crosstalk between these cell types is poorly defined. Pulmonary hypertension …

Stimuli-responsive polymeric vesicles have attracted great attention in drug delivery due to
their intrinsic hollow structures and “on demand” release of drugs upon environmental …

Inhaled medicines continue to be an essential part of treatment for respiratory diseases such
as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. In addition, inhalation …

Highlights•Nanomedicine has emerged as a field with great opportunities to improve
treatment strategies.•Pulmonary arterial hypertension (PAH) is a serious and incurable …